Form 4: Plus Therapeutics Director Acquires Stock Options

Robert P. Lenk, a director of Plus Therapeutics, Inc., acquired stock options exercisable for 40,122 shares of common stock on February 18, 2025.

Summary

• On February 18, 2025, Robert P. Lenk, a director of Plus Therapeutics, Inc., was granted stock options.
• These options allow him to purchase 40,122 shares of the company's common stock at an exercise price of $1.18 per share.
• The options vest monthly over 12 months from the grant date, with full vesting occurring at the Issuer's 2026 Annual Stockholder Meeting, contingent on continued service.
• The options expire on February 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed as a positive sign of alignment between management and shareholders. It's a neutral to slightly positive event.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the interests of directors with the company's long-term success.

Key Dates

Keywords

stock options, director, PSTV, Plus Therapeutics, beneficial ownership, Form 4